The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer
June 27th 2017Alexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.